Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 11, 2026
Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes.
Journal: Cancer medicine
Published: March 05, 2025
Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case report.
Journal: Frontiers in oncology
Published: September 27, 2024
Expanding the clinical utility of liquid biopsy by using liquid transcriptome and artificial intelligence.
Journal: The journal of liquid biopsy
Published: September 08, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Journal: Lancet (London, England)
Published: August 09, 2023
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 19, 2023
Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors.
Journal: Heliyon
Published: March 16, 2023
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Journal: Cancer
Published: December 05, 2022
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 27, 2022
Last Updated: 09/26/2026